# US 2004/0072992 A1 · Novel peptide capable of specifically acting on biological membrane

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2004/0072992 A1
- Document ID: US20040072992A1
- Status: Published application
- Kind: A1
- Application number: 10/651,563
- Filed: 2003-08-29
- Published: 2004-04-15
- Earliest claimed: 2002-08-30
- Inventors: Sachiko Machida; Ken Tokuyasu; Shigeru Matsunaga; Yoshikiyo Sakakibara; Masuko Kobori; Zhesheng Wen
- Web page: https://patentgrep.com/patent/US20040072992A1

## CPC

- C07K 7/06: having 5 to 11 amino acids
- C07K 7/08: having 12 to 20 amino acids (gastrins C07K14/595; somatostatins C07K14/655; melanotropins C07K14/68)
- C07K 14/001: {by chemical synthesis}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

A peptide is provided, consisting of amino acid sequence comprising an amino acid sequence Z1X1X2X3Z2X4X5Z3X6X7X8Z4X9. where X1-X9 are any amino acids and at least two amino acids of Z1-Z4 are basic amino acids. An analog thereof is also provided.

## Claims

### Claim 1

A peptide consisting of amino acid sequence comprising an amino acid sequence Z1X1X2X3Z2X4X5Z3X6X7X8Z4X9, wherein X1-X9 are any amino acids and at least two amino acids of Z1-Z4 are basic amino acids, or an analog thereof.

### Claim 2 (depends on 1)

The peptide of claim 1 or an analog thereof, wherein the basic amino acids are lysine (K) or arginine (R).

### Claim 3 (depends on 1)

The peptide of claim 1 or an analog thereof, wherein at least two amino acids of the X1-X9 are hydrophobic amino acids.

### Claim 4 (depends on 1)

The peptide of claim 1 comprising a sequence selected from the group consisting of ALR, WALR, WGALR, RLAWG, GWALR, RVL, KVL, RVG, KVG, GVR, VGR, RVA, RSV, RVS, KVS, SVK, and VSK, or an analog thereof.

### Claim 5 (depends on 1)

The peptide of claim 1 comprising a sequence selected from the group consisting of ALR, RLAWG, GWALR, RVL, KVL, RVG, and KVG, or an anolog thereof.

### Claim 6 (depends on 1)

The peptide of claim 1 comprising a sequence selected from the group consisting of ALR, KVL, and RVG, or an anolog thereof.

### Claim 7

A peptide capable of specifically acting on a membrane of a microorganism, comprising a sequence selected from the group consisting of ALR, WALR, WGALR, RLAWG, GWALR, RVL, KVL, RVG, KVG, GVR, VGR, RVA, RSV, RVS, KVS, SVK, and VSK, or an anolog thereof.

### Claim 8 (depends on 7)

The peptide of claim 7 or an analog thereof, wherein the microorganism causes putrefaction of food or industrial products.

### Claim 9 (depends on 7)

The peptide of claim 7 comprising a sequence selected from the group consisting of ALR, RLAWG, GWALR, RVL, KVL, RVG, and KVG, or an analog thereof.

### Claim 10 (depends on 7)

The peptide of claim 7 comprising a sequence selected from the group consisting of ALR, KVL, and RVG, or an analog thereof.

### Claim 11

A peptide capable of specifically acting on a membrane of an animal cell having an abnormality, comprising a sequence selected from the group consisting of ALR, WALR, WGALR, RLAWG, GWALR, RVL, KVL, RVG, KVG, GVR, VGR, RVA, RSV, RVS, KVS, SVK, and VSK, or an analog thereof.

### Claim 12 (depends on 11)

The peptide of claim 11 or an analog thereof, wherein the animal cell having an abnormality is a cancer cell.

### Claim 13 (depends on 12)

The peptide of claim 12, comprising a sequence selected from the group consisting of ALR, RLAWG, GWALR, RVL, KVL, RVG, and KVG, or an analog thereof.

### Claim 14 (depends on 12)

The peptide of claim 12, comprising a sequence selected from the group consisting of ALR, KVL, and RVG, or an analog thereof.

### Claim 15 (depends on 11)

The peptide of claim 11 or an analog thereof, wherein the animal cell having an abnormality is an apoptotic cell.

### Claim 16 (depends on 15)

The peptide of claim 15, comprising a sequence selected from the group consisting of ALR, RLAWG, GWALR, RVL, KVL, RVG, and KVG, or an analog thereof.

### Claim 17 (depends on 15)

The peptide of claim 15, comprising a sequence selected from the group consisting of ALR, KVL, and RVG, or an analog thereof.

### Claim 18

A peptide, comprising:
i) a first sequence selected from the group consisting of ALR, WALR, WGALR, RLAWG, GWALR, RVL, KVL, RVG, KVG, GVR, VGR, RVA, RSV, RVS, KVS, SVK, and VSK;
ii) a second sequence selected from the group consisting of ALR, WALR, WGALR, RLAWG, GWALR, RVL, KVL, RVG, KVG, GVR, VGR, RVA, RSV, RVS, KVS, SVK, and VSK; and
iii) a third sequence selected from the group consisting of ALR, WALR, WGALR, RLAWG, GWALR, RVL, KVL, RVG, KVG, GVR, VGR, RVA, RSV, RVS, KVS, SVK, and VSK.

### Claim 19

A peptide, comprising a repeat of at least three sequences of KVL or ALR.

### Claim 20

A peptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 11 to SEQ ID NO: 122, or an analog thereof.

### Claim 21

A peptide capable of specifically acting on a membrane of a microorganism, comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 11 to SEQ ID NO: 122, or an analog thereof.

### Claim 22 (depends on 21)

The peptide of claim 21 or an analog thereof, wherein the microorganism causes putrefaction of food or industrial products.

### Claim 23

A peptide capable of specifically acting on a membrane of an animal cell having an abnormality, comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 11 to SEQ ID NO: 122, or an analog thereof.

### Claim 24 (depends on 23)

The peptide of claim 23 or an analog thereof, wherein the animal cell having an abnormality is a cancer cell.

### Claim 25 (depends on 23)

The peptide of claim 23 or an analog thereof, wherein the animal cell having an abnormality is an apoptotic cell.

### Claim 26

A peptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 11 to SEQ ID NO: 122 or a variant thereof, wherein the variant has at least one amino acid deletion, addition, and/or substitution in the amino acid sequence, and maintains a property of specifically acting on a membrane of a microorganism.

### Claim 27 (depends on 26)

The peptide of claim 26 or a variant thereof, wherein the microorganism causes putrefaction of food or industrial products.

### Claim 28

A peptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 11 to SEQ ID NO: 122 or a variant thereof, wherein the variant has at least one amino acid deletion, addition, and/or substitution in the amino acid sequence, and maintains a property of specifically acting on a membrane of an animal cell having an abnormality.

### Claim 29 (depends on 28)

The peptide of claim 28 or a variant thereof, wherein the animal cell having an abnormality is a cancer cell.

### Claim 30 (depends on 28)

The peptide of claim 28 or a variant thereof, wherein the animal cell having an abnormality is an apoptotic cell.

### Claim 31

A peptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 11 to SEQ ID NO: 122 or a variant thereof, wherein the variant has at least one conservative amino acid substitution in the amino acid sequence, and maintains a property of specifically acting on a membrane of a microorganism.

### Claim 32 (depends on 31)

The peptide of claim 31 or a variant thereof, wherein the microorganism causes putrefaction of food or industrial products.

### Claim 33

A peptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 11 to SEQ ID NO: 122 or a variant thereof, wherein the variant has at least one conservative amino acid substitution in the amino acid sequence, and maintains a property of specifically acting on a membrane of an animal cell having an abnormality.

### Claim 34 (depends on 33)

The peptide of claim 33 or a variant thereof, wherein the animal cell having an abnormality is a cancer cell.

### Claim 35 (depends on 33)

The peptide of claim 33 or a variant thereof, wherein the animal cell having an abnormality is an apoptotic cell.

### Claim 36

A peptide comprising a sequence RNWRGIAGMARRLLGRNWRLM or an analog thereof, wherein the peptide or the analog thereof has an ability to act on a membrane of a microorganism at least two fold higher than a peptide comprising a sequence KNWRGIAGMAKKLLGKNWKLM.

### Claim 37 (depends on 36)

The peptide of claim 36 or an analog thereof, wherein the microorganism causes putrefaction of food or industrial products.

### Claim 38

A peptide comprising a sequence RNWRGIAGMARRLLGRNWRLM or an analog thereof, wherein the peptide or the analog thereof has an ability to act on a membrane of an animal cell having an abnormality at least two fold higher than a peptide comprising a sequence KNWRGIAGMAKKLLGKNWKLM.

### Claim 39 (depends on 38)

The peptide of claim 38 or an analog thereof, wherein the animal cell having an abnormality is a cancer cell.

### Claim 40 (depends on 38)

The peptide of claim 38 or an analog thereof, wherein the animal cell having an abnormality is an apoptotic cell.

### Claim 41

A peptide comprising a sequence RNWRGIAGMARRLLGRNWRLM or a variant thereof, wherein the variant has at least one amino acid deletion, addition, and/or substitution in the sequence-, maintains a property of specifically acting on a membrane of a microorganism, and has an ability to act on a membrane of a microorganism at least two fold higher than a peptide having a sequence KNWRGIAGMAKKLLGKNWKLM.

### Claim 42 (depends on 41)

The peptide of claim 41 or a variant thereof, wherein the microorganism causes putrefaction of food or industrial products.

### Claim 43

A peptide comprising a sequence RNWRGIAGMARRLLGRNWRLM or a variant thereof, wherein the variant has at least one amino acid deletion, addition, and/or substitution in the sequence, maintains a property of specifically acting on a membrane of an animal cell having an abnormality, and has an ability to act on a membrane of an animal cell having an abnormality at least two fold higher than a peptide having a sequence KNWRGIAGMAKKLLGKNWKLM.

### Claim 44 (depends on 43)

The peptide of claim 43 or an analog thereof, wherein the animal cell having an abnormality is a cancer cell.

### Claim 45 (depends on 43)

The peptide of claim 43 or an analog thereof, wherein the animal cell having an abnormality is an apoptotic cell.

### Claim 46

A peptide comprising a sequence RNWRGIAGMARRLLGRNWRLM or a variant thereof, wherein the variant has at least one conservative amino acid substitution excluding K or R in the sequence, maintains a property of specifically acting a membrane of a microorganism, and has an ability to act on a membrane of a microorganism at least two fold higher than a peptide having a sequence KNWRGIAGMAKKLLGKNWKLM.

### Claim 47 (depends on 46)

The peptide of claim 46 or an analog thereof, wherein the microorganism causes putrefaction of food or industrial products.

### Claim 48

A peptide comprising a sequence RNWRGIAGMARRLLGRNWRLM or a variant thereof, wherein the variant has at least one conservative substitution excluding K or R in the sequence, maintains a property of specifically acting on a membrane of an animal cell having an abnormality, and has an ability to act on an ability to act on a membrane of an animal cell having an abnormality at least two fold higher than a peptide having a sequence KNWRGIAGMAKKLLGKNWKLM.

### Claim 49 (depends on 48)

The peptide of claim 48 or an analog thereof, wherein the animal cell having an abnormality is a cancer cell.

### Claim 50 (depends on 48)

The peptide of claim 48 or an analog thereof, wherein the animal cell having an abnormality is an apoptotic cell.

### Claim 51

A library, comprising a plurality of nucleic acid sequences, each nucleic acid sequence comprising:
(1) a first cassette comprising a base sequence encoding a first peptide;
(2) a second cassette comprising a base sequence encoding a second peptide, said base sequence having the same reading frame as that of the base sequence encoding the first peptide, wherein the second peptide comprises a site allowing flexible movement of the first peptide: and
(3) a third cassette comprising a base sequence essentially required for transcription and translation of the first and the second cassette, the third cassette being operatively linked to the first and second cassettes,
wherein the number of the nucleic acid sequences in the library whose first cassettes are different from one another is at least two.

### Claim 52 (depends on 51)

The library of claim 51, wherein the second cassette further comprises a base sequence encoding a tag sequence.

### Claim 53 (depends on 51)

The library of claim 51, wherein the first cassette does not-comprise a termination codon.

### Claim 54 (depends on 51)

The library of claim 51, wherein the number of the nucleic acid sequences whose first cassettes are different from one another is at least 100.

### Claim 55 (depends on 51)

The library of claim 51, wherein the number of the nucleic acid sequences whose first cassettes are different from one another is at least 1000.

### Claim 56 (depends on 51)

A vector comprising the library of claim 51.

### Claim 57

A method for screening for a nucleic acid encoding a peptide capable of acting on a biological membrane, the method comprising the steps of.:
constructing a DNA library;
preparing peptides by transcription and translation of DNAs of the library in a cell-free system, and forming complexes of the peptide, a ribosome, and mRNA; and
selecting the complex capable of specifically binding to a membrane model.

### Claim 58 (depends on 51, 57)

The method of claim 57, wherein the DNA library comprises the library of claim 51.

### Claim 59 (depends on 53, 57)

The method of claim 57, wherein the DNA library comprises the library of claim 53.

### Claim 60 (depends on 57)

The method of claim 57, wherein the membrane model is an artificial lipid bilayer imitating a cell membrane structure of an organism.

### Claim 61 (depends on 57)

The method of claim 57, wherein the membrane model is a membrane model immobilized on a solid phase.

### Claim 62 (depends on 61)

The method of claim 61, wherein the solid phase is a magnetic bead.

### Claim 63 (depends on 57)

The method of claim 57, further comprising reverse-transcribing mRNA in the selected complex to DNA.

### Claim 64 (depends on 63)

The method of claim 63, wherein a DNA library is prepared using DNA obtained in the reverse-transcription step, and the complex forming step, the complex selecting step, and the reverse-transcription step are repeated.

### Claim 65 (depends on 64)

The method of claim 64, wherein the number of the repetitions is at least 4.

### Claim 66 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 18, 19, 20, 21, 26, 31, 36, 41)

A pharmaceutical composition for killing a microorganism, comprising the peptide of any one of claims 1 to 10, 18 to 21, 26, 31, 36, 41, and 46, or an analog or variant thereof.

### Claim 67 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 18, 19, 20, 21, 26, 31, 36, 41)

A pharmaceutical composition for preventing putrefaction of food or industrial products, comprising the peptide of any one of claims 1 to 10, 18 to 21, 26, 31, 36, 41, and 46, or an analog or variant thereof.

### Claim 68 (depends on 6, 10, 19, 21, 26, 31, 36, 41)

A pharmaceutical composition for killing a microorganism, comprising the peptide of any one of claims 6, 10, 19, 21, 26, 31, 36, 41, and 46, or an analog or variant thereof.

### Claim 69 (depends on 6, 10, 19, 21, 26, 31, 36, 41)

A pharmaceutical composition for preventing putrefaction of food or industrial products, comprising the peptide of any one of claims 6, 10, 19, 21, 26, 31, 36, 41, and 46, or an analog or variant thereof.

### Claim 70 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 18, 19, 20, 21, 26, 31, 36, 41)

A pharmaceutical composition for treating an infectious disease caused by a microorganism, comprising the peptide of any one of claims 1 to 10, 18 to 21, 26, 31, 36, 41, and 46, or an analog or variant thereof.

### Claim 71 (depends on 6, 10, 19, 21, 26, 31, 36, 41)

A pharmaceutical composition for treating an infectious disease caused by a microorganism, comprising the peptide of any one of claims 6, 10, 19, 21, 26, 31, 36, 41, and 46, or an analog or variant thereof.

### Claim 72 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 18, 19, 20, 21, 26, 31, 36, 41)

An antibiotic comprising the peptide of any one of claims 1 to 10, 18 to 21, 26, 31, 36, 41, and 46, or an analog or variant thereof.

### Claim 73 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 18, 19, 20, 21, 26, 31, 36, 41)

A pharmaceutical delivery substance for delivering a drug to a site infected with a microorganism, comprising the peptide of any one of claims 1 to 10, 18 to 21, 26, 31, 36, 41, and 46, or an analog or variant thereof.

### Claim 74 (depends on 6, 10, 19, 21, 26, 31, 36, 41)

A pharmaceutical delivery substance for delivering a drug to a site infected with a microorganism, comprising the peptide of any one of claims 6, 10, 19, 21, 26, 31, 36, 41, and 46, or an analog or variant thereof.

### Claim 75 (depends on 1, 2, 3, 4, 5, 6, 12, 13, 14, 18, 19, 20, 24, 29, 34, 39, 44)

A pharmaceutical composition for treating a cancer, comprising the peptide of any one of claims 1 to 6, 12 to 14, 18 to 20, 24, 29, 34, 39, 44, and 49, or an analog or variant thereof.

### Claim 76 (depends on 6, 14, 19, 24, 29, 34, 39, 44)

A pharmaceutical composition for treating a cancer, comprising the peptide of any one of claims 6, 14, 19, 24, 29, 34, 39, 44, and 49, or an analog or variant thereof.

### Claim 77 (depends on 1, 2, 3, 4, 5, 6, 12, 13, 14, 18, 19, 20, 24, 29, 34, 39, 44)

A pharmaceutical delivery substance for delivering a drug to a cancer lesion site, comprising the peptide of any one of claims 1 to 6, 12 to 14, 18 to 20, 24, 29, 34, 39, 44, and 49, or an analog or variant thereof.

### Claim 78 (depends on 6, 14, 19, 24, 29, 34, 39, 44)

A pharmaceutical delivery substance for delivering a drug to a cancer lesion site, comprising the peptide of any one of claims 6, 14, 19, 24, 29, 34, 39, 44, and 49, or an analog or variant thereof.

### Claim 79 (depends on 1, 2, 3, 4, 5, 6, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45)

A pharmaceutical composition for suppressing apoptosis, comprising the peptide of any one of claims 1 to 6, 15 to 20, 25, 30, 35, 40, 45, and 50, or an analog or variant thereof.

### Claim 80 (depends on 6, 17, 19, 25, 30, 35, 40, 45)

A pharmaceutical composition for suppressing apoptosis, comprising the peptide of any one of claims 6, 17, 19, 25, 30, 35, 40, 45, and 50, or an analog or variant thereof.

### Claim 81 (depends on 1, 2, 3, 4, 5, 6, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45)

A pharmaceutical delivery substance for delivering a drug to a site undergoing apoptosis, comprising the peptide of any one of claims 1 to 6, 15 to 20, 25, 30, 35, 40, 45, and 50, or an analog or variant thereof.

### Claim 82 (depends on 6, 17, 19, 25, 30, 35, 40, 45)

A pharmaceutical delivery substance for delivering a drug to a site undergoing apoptosis, comprising the peptide of any one of claims 6, 17, 19, 25, 30, 35, 40, 45, and 50, or an analog or variant thereof.

### Claim 83

A kit for screening for a nucleic acid encoding a peptide capable of acting on a biological membrane, the kit comprising:
a lipid for preparing a membrane model.

### Claim 84 (depends on 83)

The kit of claim 83, further comprising an enzyme and ribosome for forming a peptide-ribosome-mRNA complex in a cell-free system.

### Claim 85 (depends on 84)

The kit of claim 84, wherein the enzyme and the ribosome are provided as cell free extracts.

### Claim 86 (depends on 85)

The kit of claim 85, wherein the cell free extract is S30 extract, i.e., E. coli extract.

### Claim 87 (depends on 51, 83)

The kit of claim 83, further comprising the library of claim 51.

### Claim 88 (depends on 53, 83)

The kit of claim 83, further comprising the library of claim 53.

### Claim 89

A pharmaceutical composition for killing a microorganism, comprising a peptide having an amino acid sequence selected from the group consisting of SEQ ID NOs: 5, 107, 121, and 122, or an analog or variant thereof.

### Claim 90

A pharmaceutical composition for preventing putrefaction food or industrial products, comprising a peptide having an amino acid sequence selected from the group consisting of SEQ ID NOs: 5, 107, 121, and 122, or an analog or variant thereof.

### Claim 91

A pharmaceutical composition for treating an infectious disease caused by a microorganism, comprising a peptide having an amino acid sequence selected from the group consisting of SEQ ID NOs: 5, 107, 121, and 122, or an analog or variant thereof.

### Claim 92 (depends on 91)

The pharmaceutical composition of claim 91, wherein the microorganism is pathogenic to an animal.

### Claim 93 (depends on 91)

The pharmaceutical composition of claim 91, wherein the microorganism is pathogenic to a plant.

### Claim 94 (depends on 93)

The pharmaceutical composition of claim 93, wherein the plant pathogenic microorganism is Erwinia carotovora.

### Claim 95

A pharmaceutical composition for treating a cancer, comprising a peptide having an amino acid sequence selected from the group consisting of SEQ ID NOs: 5, 107, 121, and 122, or an analog or variant thereof.

### Claim 96 (depends on 95)

The pharmaceutical composition of claim 95, wherein the cancer is selected from the group consisting of bladder cancer, stomach cancer, breast cancer, lung cancer, prostate cancer, glioblastoma, large intestine cancer, uterine cancer, ovarian cancer, kidney cancer, and leukemia.
